Company announces first study (STARDUST) to explore a treat-to-target (TTT) strategy for ustekinumab in Crohn's Disease using endoscopic response to guide treatment

TTT is a proactive treatment strategy where frequently monitored outcomes e.g. endoscopic response, biomarkers and clinical symptoms, guide use of the medication. Interim analysis found, of 220 responders in TTT arm, 37% achieved endoscopic response at week 16.

Source:

PharmaTimes